Last updated: February 27, 2026
What is NDC 43598-0453?
NDC 43598-0453 identifies Rituximab (prescription drug), commonly marketed under the brand name Rituxan. It is approved for treating various hematologic cancers, autoimmune diseases, and off-label indications.
Market Size and Sales Data
Global sales of Rituximab reached approximately $4.5 billion in 2022, with expected compound annual growth rate (CAGR) of roughly 4% through 2027. Sales concentrations include North America (about 60%), Europe (~20%), and the Asia-Pacific (~15%).
- U.S. sales in 2022: ~$2.7 billion.
- Major indications driving revenue:
- Non-Hodgkin lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (RA)
- Other autoimmune conditions
Key market players include Roche (the patent holder), with biosimilar entrants launching in multiple regions since patent expiration in late 2022.
Patent and Regulatory Landscape
- Roche held patents expiring in late 2022. Biosimilar versions are now available.
- The biosimilar market for rituximab is expected to expand rapidly, with anticipated generic entry reducing prices.
- The FDA approved several biosimilars beginning in 2019, leading to increased competition.
Price Trends and Projections
Current Pricing
- U.S. average selling price (ASP): approximately $5,000 per 100 mg vial.
- Standard regimens take 375 mg/m² weekly for 4 weeks for initial treatment, with treatment costs exceeding $50,000 per course.
- Biosimilars are priced 20-30% lower than the originator, with some vendors offering prices as low as $3,000 per vial.
Projected Price Trends
| Year |
Estimated Average Price per Vial |
Comments |
| 2023 |
$4,000 - $4,500 |
Post-biosimilar entry, price reductions stabilize. |
| 2025 |
$3,500 - $4,000 |
Increased biosimilar competition reduces originator price. |
| 2027 |
$3,000 - $3,500 |
Market saturation with biosimilars further drives down prices. |
Price Drivers
- Biosimilar uptake rates will determine price erosion.
- Regulatory policies favoring biosimilar substitution in key markets.
- Healthcare payer policies pushing for cost-effective therapies.
- Manufacturing efficiencies lowering production costs for biosimilars.
Future Price Considerations
- The emergence of "super-biosimilars" and biobetters could further change price dynamics.
- Patent litigation and legal delays may influence biosimilar market penetration timelines.
- Contract pricing and negotiated discounts with payers impact net prices further.
Competitive Landscape
| Company |
Product Name |
Launch Year |
Market Share (2022) |
Price (approximate) |
Notes |
| Roche |
Rituxan |
1997 |
50% |
$5,000/vial |
Original biologic; dominant before biosimilars. |
| Celltrion/Teva |
Truxima |
2018 |
20% |
$3,700/vial |
First biosimilar approved in US. |
| Sandoz, Biogen |
Ruxience |
2019 |
10% |
$3,200/vial |
Biosimilar with aggressive pricing. |
| other biosimilars |
Various |
2019–2023 |
20% combined |
$3,000-$3,500/vial |
Growing biosimilar proliferation. |
Regulatory and Reimbursement Trends
- Payers favor biosimilars due to lower costs, incentivizing switching from originator.
- US Medicare and Medicaid coverage policies favor biosimilars, accelerating adoption.
- Europe, especially Germany and the UK, promotes biosimilar substitution, pressing prices downward.
Key Takeaways
- The global rituximab market was ~$4.5 billion in 2022, with biosimilar adoption impacting pricing.
- Prices for originator drugs are declining, with projections showing a 30-40% reduction by 2027.
- Biosimilar competition is expected to dominate the market, further pressuring prices.
- Strategic focus should be on biosimilar pipeline development and regulatory trends influencing uptake.
FAQs
Q1: Will the price of rituximab rebound post-biosimilar entry?
A: No; biosimilar entry typically leads to sustained price decreases, barring regulatory or patent litigation changes.
Q2: How quickly are biosimilars capturing market share?
A: Biosimilars have gained a combined market share of approximately 30% in the U.S. within three years of approval.
Q3: Are biosimilar prices in the U.S. comparable to those in Europe?
A: U.S. prices are generally higher due to different reimbursement policies; European biosimilars often see deeper discounts.
Q4: What factors could disrupt current price projections?
A: Patent litigation, regulatory delays, or slower biosimilar adoption due to physician or payer preferences.
Q5: What are the implications for manufacturers?
A: Investment in biosimilar development and strategic pricing will be critical to maintain profitability amid fierce competition.
Sources:
- EvaluatePharma. (2023). Global Oncology Market Report.
- IQVIA. (2022). Biosimilar Trends and Market Share Reports.
- FDA. (2023). Approved Biosimilars.
- Novartis. (2023). Biosimilar Market Strategies.
- Medicare.gov. (2023). Coverage and Reimbursement policies for biosimilars.
[1] EvaluatePharma. (2023). Global Oncology Market Report.
